Association between MnSOD polymorphism and prostate cancer risk
| Categories . | MnSOD genotype . | . | . | |||
|---|---|---|---|---|---|---|
| . | VV . | VA . | AA . | |||
| Controls, N | 190 | 379 | 195 | |||
| All prostate cancer (567 cases) | ||||||
| Cases, N | 132 | 288 | 147 | |||
| RR (95% CI) | 1.00 (Reference) | 1.09 (0.84-1.43) | 1.09 (0.80-1.49) | |||
| By disease status* | ||||||
| Nonaggressive prostate cancer (281 cases) | ||||||
| Cases, N | 67 | 143 | 71 | |||
| RR (95% CI) | 1.00 (Reference) | 1.06 (0.75-1.49) | 1.01 (0.68-1.50) | |||
| Aggressive prostate cancer (275 cases) | ||||||
| Cases, N | 64 | 139 | 72 | |||
| RR (95% CI) | 1.00 (Reference) | 1.09 (0.77-1.54) | 1.10 (0.74-1.62) | |||
| Categories . | MnSOD genotype . | . | . | |||
|---|---|---|---|---|---|---|
| . | VV . | VA . | AA . | |||
| Controls, N | 190 | 379 | 195 | |||
| All prostate cancer (567 cases) | ||||||
| Cases, N | 132 | 288 | 147 | |||
| RR (95% CI) | 1.00 (Reference) | 1.09 (0.84-1.43) | 1.09 (0.80-1.49) | |||
| By disease status* | ||||||
| Nonaggressive prostate cancer (281 cases) | ||||||
| Cases, N | 67 | 143 | 71 | |||
| RR (95% CI) | 1.00 (Reference) | 1.06 (0.75-1.49) | 1.01 (0.68-1.50) | |||
| Aggressive prostate cancer (275 cases) | ||||||
| Cases, N | 64 | 139 | 72 | |||
| RR (95% CI) | 1.00 (Reference) | 1.09 (0.77-1.54) | 1.10 (0.74-1.62) | |||
Aggressive prostate cancer, stage C or D, high-grade tumor (Gleason score 7-10), or prostate cancer deaths during the follow-up; nonaggressive prostate cancer, stage A or B and low-grade (Gleason score 2-6) tumor; 11 cases with unknown disease status were excluded.